Phosphorylation of TCTP as a marker for polo-like kinase-1 activity in vivo

Ulisse Cucchi, Laura M. Gianellini, Anna De Ponti, Francesco Sola, Rachele Alzani, Veronica Patton, Alice Pezzoni, Sonia Troiani, Maria B. Saccardo, Simona Rizzi, Maria L. Giorgini, Paolo Cappella, Italo Beria, Barbara Valsasina

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Polo-like kinase 1 (PLK1) is the master regulator of mitosis and a target for anticancer therapy. To develop a marker of PLK1 activity in cells and tumour tissues, this study focused on translational controlled tumour protein (TCTP) and identified serine 46 as a site phosphorylated by PLK1 in vitro. Using an antibody raised against phosphoTCTP-Ser46, it was demonstrated that phosphorylation at this site correlates with PLK1 level and kinase activity in cells. Moreover, PLK1 depletion by siRNA or inactivation by specific inhibitors caused a correspondent decrease in phospho-TCTP-Ser46 signal validating this site as a direct marker of PLK1. Using this marker, the study characterized PLK1 inhibitors in cells by setting up a high-content assay and finally immunohistochemical assay suitable for following inhibitor activity in preclinical tumour models and possibly in clinical studies was developed.

Original languageEnglish
Pages (from-to)4973-4986
Number of pages14
JournalAnticancer Research
Volume30
Issue number12
Publication statusPublished - Dec 2010

Fingerprint

Phosphorylation
Neoplasms
Proteins
polo-like kinase 1
Mitosis
Serine
Small Interfering RNA
Phosphotransferases
Antibodies
Therapeutics

Keywords

  • Antitumor activity
  • Biomarker
  • PLK1
  • TCTP

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cucchi, U., Gianellini, L. M., De Ponti, A., Sola, F., Alzani, R., Patton, V., ... Valsasina, B. (2010). Phosphorylation of TCTP as a marker for polo-like kinase-1 activity in vivo. Anticancer Research, 30(12), 4973-4986.

Phosphorylation of TCTP as a marker for polo-like kinase-1 activity in vivo. / Cucchi, Ulisse; Gianellini, Laura M.; De Ponti, Anna; Sola, Francesco; Alzani, Rachele; Patton, Veronica; Pezzoni, Alice; Troiani, Sonia; Saccardo, Maria B.; Rizzi, Simona; Giorgini, Maria L.; Cappella, Paolo; Beria, Italo; Valsasina, Barbara.

In: Anticancer Research, Vol. 30, No. 12, 12.2010, p. 4973-4986.

Research output: Contribution to journalArticle

Cucchi, U, Gianellini, LM, De Ponti, A, Sola, F, Alzani, R, Patton, V, Pezzoni, A, Troiani, S, Saccardo, MB, Rizzi, S, Giorgini, ML, Cappella, P, Beria, I & Valsasina, B 2010, 'Phosphorylation of TCTP as a marker for polo-like kinase-1 activity in vivo', Anticancer Research, vol. 30, no. 12, pp. 4973-4986.
Cucchi U, Gianellini LM, De Ponti A, Sola F, Alzani R, Patton V et al. Phosphorylation of TCTP as a marker for polo-like kinase-1 activity in vivo. Anticancer Research. 2010 Dec;30(12):4973-4986.
Cucchi, Ulisse ; Gianellini, Laura M. ; De Ponti, Anna ; Sola, Francesco ; Alzani, Rachele ; Patton, Veronica ; Pezzoni, Alice ; Troiani, Sonia ; Saccardo, Maria B. ; Rizzi, Simona ; Giorgini, Maria L. ; Cappella, Paolo ; Beria, Italo ; Valsasina, Barbara. / Phosphorylation of TCTP as a marker for polo-like kinase-1 activity in vivo. In: Anticancer Research. 2010 ; Vol. 30, No. 12. pp. 4973-4986.
@article{e827faa2a76548c8922774b268622b4f,
title = "Phosphorylation of TCTP as a marker for polo-like kinase-1 activity in vivo",
abstract = "Polo-like kinase 1 (PLK1) is the master regulator of mitosis and a target for anticancer therapy. To develop a marker of PLK1 activity in cells and tumour tissues, this study focused on translational controlled tumour protein (TCTP) and identified serine 46 as a site phosphorylated by PLK1 in vitro. Using an antibody raised against phosphoTCTP-Ser46, it was demonstrated that phosphorylation at this site correlates with PLK1 level and kinase activity in cells. Moreover, PLK1 depletion by siRNA or inactivation by specific inhibitors caused a correspondent decrease in phospho-TCTP-Ser46 signal validating this site as a direct marker of PLK1. Using this marker, the study characterized PLK1 inhibitors in cells by setting up a high-content assay and finally immunohistochemical assay suitable for following inhibitor activity in preclinical tumour models and possibly in clinical studies was developed.",
keywords = "Antitumor activity, Biomarker, PLK1, TCTP",
author = "Ulisse Cucchi and Gianellini, {Laura M.} and {De Ponti}, Anna and Francesco Sola and Rachele Alzani and Veronica Patton and Alice Pezzoni and Sonia Troiani and Saccardo, {Maria B.} and Simona Rizzi and Giorgini, {Maria L.} and Paolo Cappella and Italo Beria and Barbara Valsasina",
year = "2010",
month = "12",
language = "English",
volume = "30",
pages = "4973--4986",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "12",

}

TY - JOUR

T1 - Phosphorylation of TCTP as a marker for polo-like kinase-1 activity in vivo

AU - Cucchi, Ulisse

AU - Gianellini, Laura M.

AU - De Ponti, Anna

AU - Sola, Francesco

AU - Alzani, Rachele

AU - Patton, Veronica

AU - Pezzoni, Alice

AU - Troiani, Sonia

AU - Saccardo, Maria B.

AU - Rizzi, Simona

AU - Giorgini, Maria L.

AU - Cappella, Paolo

AU - Beria, Italo

AU - Valsasina, Barbara

PY - 2010/12

Y1 - 2010/12

N2 - Polo-like kinase 1 (PLK1) is the master regulator of mitosis and a target for anticancer therapy. To develop a marker of PLK1 activity in cells and tumour tissues, this study focused on translational controlled tumour protein (TCTP) and identified serine 46 as a site phosphorylated by PLK1 in vitro. Using an antibody raised against phosphoTCTP-Ser46, it was demonstrated that phosphorylation at this site correlates with PLK1 level and kinase activity in cells. Moreover, PLK1 depletion by siRNA or inactivation by specific inhibitors caused a correspondent decrease in phospho-TCTP-Ser46 signal validating this site as a direct marker of PLK1. Using this marker, the study characterized PLK1 inhibitors in cells by setting up a high-content assay and finally immunohistochemical assay suitable for following inhibitor activity in preclinical tumour models and possibly in clinical studies was developed.

AB - Polo-like kinase 1 (PLK1) is the master regulator of mitosis and a target for anticancer therapy. To develop a marker of PLK1 activity in cells and tumour tissues, this study focused on translational controlled tumour protein (TCTP) and identified serine 46 as a site phosphorylated by PLK1 in vitro. Using an antibody raised against phosphoTCTP-Ser46, it was demonstrated that phosphorylation at this site correlates with PLK1 level and kinase activity in cells. Moreover, PLK1 depletion by siRNA or inactivation by specific inhibitors caused a correspondent decrease in phospho-TCTP-Ser46 signal validating this site as a direct marker of PLK1. Using this marker, the study characterized PLK1 inhibitors in cells by setting up a high-content assay and finally immunohistochemical assay suitable for following inhibitor activity in preclinical tumour models and possibly in clinical studies was developed.

KW - Antitumor activity

KW - Biomarker

KW - PLK1

KW - TCTP

UR - http://www.scopus.com/inward/record.url?scp=78751477698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78751477698&partnerID=8YFLogxK

M3 - Article

C2 - 21187478

AN - SCOPUS:78751477698

VL - 30

SP - 4973

EP - 4986

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 12

ER -